Electrophysiology

DGAP-News: Volta Medical's AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication

Retrieved on: 
Wednesday, August 31, 2022
Volta, Machine learning, EGM, CEO, Technology, JCE, Obesity, Arrhythmia, Artificial intelligence, Brain, Ageing, Entrepreneurship, AF, Catheter ablation, Heart, Business intelligence software, Heart failure, Atrial tachycardia, Electrophysiology, Physician, Stroke, Moyamoya disease, Common, Hospital, Journal, Deep learning, MD, Paola Lattus, E-GMS, Prevalence, Hypertension, FDA, Population, EV, Algorithm, Diabetes, Atrial fibrillation, Intuition, Journal of Cardiovascular Electrophysiology, Patient, Palpitations, Medical device, Medical imaging, Pharmaceutical industry, EU

The article titled Artificial Intelligence Software Standardizes Electrogram-based Ablation Outcome for Persistent Atrial Fibrillation is available at https://onlinelibrary.wiley.com/doi/abs/10.1111/jce.15657 .

Key Points: 
  • The article titled Artificial Intelligence Software Standardizes Electrogram-based Ablation Outcome for Persistent Atrial Fibrillation is available at https://onlinelibrary.wiley.com/doi/abs/10.1111/jce.15657 .
  • Results demonstrated that VX1 allowed for the building of standardized Volta VX1 maps, used as a reference for operators to conduct EGM-guided ablation.
  • The standardization of the detection of abnormal EGMs facilitated a robust patient-to-patient and center-to-center uniformity in EGM-based ablation.
  • Furthermore, after a one-year follow-up, patients demonstrated a high freedom from atrial fibrillation and from any atrial arrhythmia, 89% and 73% after an average of 1.3 procedures per patient, respectively.

Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication

Retrieved on: 
Wednesday, August 31, 2022
Volta, Machine learning, EGM, CEO, Technology, JCE, Obesity, Arrhythmia, Artificial intelligence, Brain, Ageing, Entrepreneurship, AF, Catheter ablation, Heart, Business intelligence software, Heart failure, Atrial tachycardia, Electrophysiology, Physician, Stroke, Moyamoya disease, Common, Hospital, Journal, Deep learning, MD, GLOBE, Paola Lattus, E-GMS, Prevalence, Hypertension, FDA, Population, EV, Algorithm, Diabetes, Atrial fibrillation, Intuition, Journal of Cardiovascular Electrophysiology, Patient, Palpitations, Medical device, Medical imaging, Pharmaceutical industry, EU

The article titled Artificial Intelligence Software Standardizes Electrogram-based Ablation Outcome for Persistent Atrial Fibrillation is available at https://onlinelibrary.wiley.com/doi/abs/10.1111/jce.15657 .

Key Points: 
  • The article titled Artificial Intelligence Software Standardizes Electrogram-based Ablation Outcome for Persistent Atrial Fibrillation is available at https://onlinelibrary.wiley.com/doi/abs/10.1111/jce.15657 .
  • Results demonstrated that VX1 allowed for the building of standardized Volta VX1 maps, used as a reference for operators to conduct EGM-guided ablation.
  • The standardization of the detection of abnormal EGMs facilitated a robust patient-to-patient and center-to-center uniformity in EGM-based ablation.
  • Furthermore, after a one-year follow-up, patients demonstrated a high freedom from atrial fibrillation and from any atrial arrhythmia, 89% and 73% after an average of 1.3 procedures per patient, respectively.

BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth

Retrieved on: 
Tuesday, August 30, 2022
Online, Mayo Clinic, Wiley (publisher), COVID-19, Security (finance), Technology, NASDAQ, Awareness, Decision-making, Risk, Electrophysiology, Physician, National accounts, SEC, Workflow, U.S. Securities and Exchange Commission, Journal, Adoption, PURE, Nautilus, Inc. v. Biosig Instruments, Inc., ST, Knowledge, Acquisition, Industry, Growth, Marketing, Journal of Cardiovascular Electrophysiology, Pharmaceutical industry, Risk management, Company

BioSig recently doubled the size of its sales organization, with plans of tripling it before the fourth quarter of this year.

Key Points: 
  • BioSig recently doubled the size of its sales organization, with plans of tripling it before the fourth quarter of this year.
  • The Company appointed a new team of National Account Executives who will be strategically located throughout the U.S. to support and accelerate sales growth and adoption of the PURE EP System.
  • The new sales executives will expand the Companys growing commercial pipeline, as it continues to see an increase in medical centers entering into 60-day evaluation agreements for its novel signal processing technology.
  • I view our recent investment in our commercial, sales, and marketing teams as a complimentary catalyst for BioSigs new commercial strategy and longterm growth.

Galaxy Medical Receives CE Mark for CENTAURI Pulsed Electric Field System

Retrieved on: 
Monday, August 29, 2022
CA, Patient, CEO, Division, CE marking, Safety, Muscle contraction, SAN, WAVE1, AF, PEF, ECLIPSE, PFA, Recurrence, Galaxy, Physician, Arrhythmia, Union, Workflow, Stroke, De novo, Microbubble, MD, Connect, Atrial fibrillation, Catheter, PVI, University Clinical Hospital in Białystok, Hospital, Medical imaging, Electrophysiology

SAN CARLOS, Calif., Aug. 29, 2022 /PRNewswire/ -- Galaxy Medical today announced that it received the CE Mark for its CENTAURI Pulsed Electric Field (PEF) System and launched its commercial program.

Key Points: 
  • SAN CARLOS, Calif., Aug. 29, 2022 /PRNewswire/ -- Galaxy Medical today announced that it received the CE Mark for its CENTAURI Pulsed Electric Field (PEF) System and launched its commercial program.
  • The approval allows the company to market the system for the treatment of paroxysmal atrial fibrillation (AF) in the European Union and geographies that accept the CE Mark.
  • CENTAURI is the first commercially available system to enable PEF ablation with focal catheters which are used in the majority of cardiac ablation procedures worldwide.
  • "From the beginning, we designed CENTAURI to be the workhorse PEF system for all electrophysiology labs, enabling physicians to maintain use of their favored mapping systems and catheters," commented Jonathan Waldstreicher, MD, CEO of Galaxy Medical.

BioSig Places Second PURE EP™ System For Evaluation at Cleveland Clinic a Leading Medical Center of Excellence

Retrieved on: 
Wednesday, August 24, 2022
Online, Mayo Clinic, Wiley (publisher), COVID-19, Security (finance), Main, Technology, Research, NASDAQ, News, Cleveland Clinic, Decision-making, Risk, Electrophysiology, Physician, Cleveland, Diagnosis, SEC, Workflow, Education, U.S. News & World Report, Hospital, Journal, U.S. Securities and Exchange Commission, PURE, Company, Nautilus, Inc. v. Biosig Instruments, Inc., EP, ST, Arrhythmia, Acquisition, Journal of Cardiovascular Electrophysiology, Pharmaceutical industry, Medical device

The additional installation will support the medical centers clinical evaluation of the PURE EP System and expand physician access to the Companys signal processing technology.

Key Points: 
  • The additional installation will support the medical centers clinical evaluation of the PURE EP System and expand physician access to the Companys signal processing technology.
  • The Company recently expanded its clinical footprint in Illinois with an additional evaluation agreement at a leading medical center in Springfield, the state capital.
  • Looking ahead, BioSig will serve as a partner at the upcoming Cleveland Clinic Global EP Summit 2022 , due to take place this coming September.
  • Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.

Vektor Medical’s Technology Attracts Seasoned MedTech Experts to Lead Sales and Quality Functions

Retrieved on: 
Wednesday, August 24, 2022
Medical Devices, Health, Health Technology, Other Science, Cardiology, Science, ISO, VP, ECG, EU, Technology, 3D, Arrhythmia, Johnson & Johnson, International Organization for Standardization, Food and Drug Administration, Engineering, Solution, International Organization (journal), Ventricular fibrillation, Heart, Medicine, Medtech, NPD, Vector, Electrophysiology, Design quality indicator, Physician, Food, Multimedia, NextGen Healthcare, Leadership, FDA, LivaNova, Compliance, Implications of U.S. gene patent invalidation on Australia, MDR, Patient, Hotel manager, Medical imaging, Medical device, Vektor

Kathryn brings over a decade of quality and assurance experience to Vektors repertoire, said Rob Krummen, Vektor Medical CEO.

Key Points: 
  • Kathryn brings over a decade of quality and assurance experience to Vektors repertoire, said Rob Krummen, Vektor Medical CEO.
  • Im thrilled that Vektor has attracted leaders of Tim and Kathryns caliber given our compelling clinical data supporting vMap and early interest in the technology.
  • In his role at Vektor, he leads the commercial sales strategy and execution for vMap, while overseeing the field team.
  • Before joining Vektor Medical, Laird was Vice President of Sales in North America for Implicity, a leader in remote patient monitoring and cardiac data management solutions.

Oncolyze, a Company Aiming to Treat Cancer by Exploding Cancer Cells, is Now Accepting Investments. Own a Piece in the Future of Cancer Treatment.

Retrieved on: 
Tuesday, August 23, 2022
MedImmune, COO, Security (finance), Metastasis, CEO, Cancer, Survival, Dartmouth College, Awareness, Acute leukemia, Innovation, Doctor of Philosophy, Entrepreneurship, Death, Multiple myeloma, Colon, City, AML, Mouse, SeedInvest, Memorial Sloan Kettering Cancer Center, Northwestern University, Monroe Dunaway Anderson, LinkedIn, Diagnosis, NIH, Cedars-Sinai Medical Center, Quality of life, Investment, Electrophysiology, Acute myeloid leukemia, U.S. Securities and Exchange Commission, MD, GLOBE, Patient, FDA, University School, Final, Lymphatic system, Necrosis, Orphan drug, Johnson & Johnson, Mutation, Clinical trial, Bone marrow, Transplant, Industry, Cardiovascular disease, Pharmaceutical industry, Vaccine, Pfizer, Leukemia

Oncolyze haslaunched aRegulation A+ ("Reg A") funding campaign to spread awareness of OM-301 among cancer patients, healthcare professionals, and the investment community.

Key Points: 
  • Oncolyze haslaunched aRegulation A+ ("Reg A") funding campaign to spread awareness of OM-301 among cancer patients, healthcare professionals, and the investment community.
  • Reg A is a type of offering that allows anyone to invest in Oncolyze and receive shares in the company.
  • There are many types of cancer, but one of the deadliest is acute myelogenous leukemia (AML).
  • Patients with this blood cancer have only a 1 in 4 chance of living for five years after diagnosis.

Disrupting Data Science in Neuroscience Research and AI

Retrieved on: 
Tuesday, August 23, 2022
Machine learning, PR, University, CEO, Technology, Chief executive officer, ScienceDaily, Medtech, Research, Neuron, Gene, Disruption, Brain, White House, Solution, Computational engineering, Public opinion, Electrophysiology, Apple, Evangelist, KJ, Intelligence, BRAIN, Data analysis, Public relations, Laboratory, Student, Baylor College of Medicine, Google Play, Depression, Data science, Map, Baylor University, E-commerce, History, Neocortex, Doctor of Philosophy, Traumatic brain injury, Interrupt, Communication, Neurophysiology, App store, Industry, Environment, COVID, AI, Adoption, DONE, Medical imaging, Management, Mobile phone, Marketing, Science, Finance, Neuroscience

TAMPA BAY, Fla., Aug. 23, 2022 /PRNewswire-PRWeb/ -- In 2013, then-President Obama launched the brain initiative, which allocated funding to map every neuron in the brain. Understanding how the brain works can revolutionize the lives of many Americans, solving the complex problems of Alzheimer's and Parkinson's disease, depression, and traumatic brain injury (1). However, mapping the brain alone does not reveal how it functions. Different parts of the brain appear similar but function differently, and each person has unique brain anatomy (2).

Key Points: 
  • The need for data analysis has allocated neuroscience graduate students to solving complex computer science problems.
  • Dimitri Yatsenko's background in computer science gave him a unique perspective when his fascination with the human brain led him to neuroscience.
  • They develop data science frameworks, platforms, and services for collaborative research, focusing on neuroscience and AI.
  • While engaged in neuroscience research at Baylor College of Medicine, Dimitri started the DataJoint framework as an open source framework https://datajoint.org .

Thermedical Announces FDA Approval of Clinical Trial for SERF Ablation to Treat Patients with Ventricular Tachycardia, Leading Cause of Sudden Cardiac Death

Retrieved on: 
Monday, August 22, 2022
Research, Medical Devices, FDA, Clinical Trials, Cardiology, Biotechnology, Health, General Health, Science, Lung, Mayo Clinic, National, FHRS, Research, CEO, Durable medical equipment, Technology, Safety, Arrhythmia, Muscle tissue, SBMG, SERF, Ventricular tachycardia, ICDS, National Heart, Lung, and Blood Institute, Hope, MIT, Small Business Innovation Research, Shock, NIH, Quality of life, Multimedia, Grant (money), Breakthrough, Â, SBIR, FDA, Pharmacotherapy, Population, Defibrillation, Clinical trial, ICD, Patient, Pharmaceutical industry, Medical device, Electrophysiology

VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.

Key Points: 
  • VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.
  • VT is a leading cause of sudden cardiac death.
  • (Photo: Business Wire)
    SERF ablation with the Durablate catheter will be investigated as a treatment option for patients with ventricular arrhythmias resistant to antiarrhythmic drugs or standard ablation procedures.
  • SERF ablation provides a new form of biological heat transfer designed to be more efficient than conventional ablation methods.

Vital Heart & Vein Continues to Expand Physician Team

Retrieved on: 
Monday, August 22, 2022
Duke University, Mount Sinai Hospital, Texas Medical Center, Lettuce big-vein disease, Houston Methodist Hospital, Hinohara, Technology, CEO, Cardiology, MD, Electrophysiology, Memorial Hermann–Texas Medical Center, Medical imaging, Humble

HOUSTON, Aug. 22, 2022 /PRNewswire/ -- Vital Heart & Vein, Houston's leading cardiovascular and vein health provider, announced today that Tim Hinohara, MD, has joined the practice as part of its structural and interventional cardiology team.

Key Points: 
  • HOUSTON, Aug. 22, 2022 /PRNewswire/ -- Vital Heart & Vein, Houston's leading cardiovascular and vein health provider, announced today that Tim Hinohara, MD, has joined the practice as part of its structural and interventional cardiology team.
  • We are honored to have a physician of Dr. Hinohara's caliber joining our elite team of providers," said Gay Nord, CEO of Vital Heart & Vein.
  • Vital Heart & Vein was established in 1998 by a team of highly trained cardiologists in Houston, Texas.
  • Vital Heart & Vein strives to become a valued partner for each patient by providing individualized, accessible, and high-quality care.